Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Klamroth

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Hamostaseologie|November 26, 2016
A new era of treatment for patients with haemophilia A?Robert Klamroth
Hamostaseologie|April 30, 2024
Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous ThromboembolismBirgit Linnemann, Robert Klamroth
Hamostaseologie|February 19, 2019
Science Meets Clinical PracticeRobert Klamroth, Jürgen Koscielny
Patient Preference and Adherence|May 6, 2020
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial PatientsWolfgang Miesbach, Robert Klamroth
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 13, 2024
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experienceRobert Klamroth, Saskia Gottstein
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 30, 2020
Redefining prophylaxis in the modern eraJohnny N Mahlangu, Victor Blanchette, Robert Klamroth
Transfusion|October 15, 2013
Pathogen inactivation and removal methods for plasma-derived clotting factor concentratesRobert Klamroth, Albrecht Gröner, Toby L Simon
Deutsche Medizinische Wochenschrift (1946)|February 27, 2024
[Venous thromboembolism - was is new in the revised AWMF guideline?]Birgit Linnemann, Katja Sibylle Mühlberg, Robert Klamroth
VASA. Zeitschrift Fur Gefasskrankheiten|August 26, 2010
Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacyRobert Klamroth, S Gottstein, E Essers, et al.
Thrombosis Research|November 22, 2013
Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia ARobert Klamroth, Saskia Gottstein, Marija Orlovic, et al.
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Hamostaseologie|November 26, 2016
A new era of treatment for patients with haemophilia A?Robert Klamroth
Hamostaseologie|April 30, 2024
Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous ThromboembolismBirgit Linnemann, Robert Klamroth
Hamostaseologie|February 19, 2019
Science Meets Clinical PracticeRobert Klamroth, Jürgen Koscielny
Patient Preference and Adherence|May 6, 2020
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial PatientsWolfgang Miesbach, Robert Klamroth
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 13, 2024
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experienceRobert Klamroth, Saskia Gottstein
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 30, 2020
Redefining prophylaxis in the modern eraJohnny N Mahlangu, Victor Blanchette, Robert Klamroth
Transfusion|October 15, 2013
Pathogen inactivation and removal methods for plasma-derived clotting factor concentratesRobert Klamroth, Albrecht Gröner, Toby L Simon
Deutsche Medizinische Wochenschrift (1946)|February 27, 2024
[Venous thromboembolism - was is new in the revised AWMF guideline?]Birgit Linnemann, Katja Sibylle Mühlberg, Robert Klamroth
VASA. Zeitschrift Fur Gefasskrankheiten|August 26, 2010
Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacyRobert Klamroth, S Gottstein, E Essers, et al.
Thrombosis Research|November 22, 2013
Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia ARobert Klamroth, Saskia Gottstein, Marija Orlovic, et al.
Pageof 15